Kusatsu/Shiga, Japan — May 19, 2016 – Takara Bio Inc. announces that HF10 US Phase II clinical trial data will be presented at the 2016 Annual Meeting of the American Society of Clinical Oncology (May29 – June 2, 2016, Chicago, Illinois, U.S.)
【Outline of presentation】
|Name of conference||
ASCO(American Society of Clinical Oncology) Annual Meeting 2016
|Place||McCormick Place (Chicago, Illinois, U.S.)|
|Date||June 4 (local time)|
|Title||Preliminary results from Phase II Study of Combination Treatment with HF10, a Replication-competent HSV-1 Oncolytic Virus, and Ipilimumab in Patients with Stage IIIB, IIIC, or IV Unresectable or Metastatic Melanoma|
The interim results of Phase II clinical trial for oncolytic virus HF10 in the U.S.[Enrollment progress ]- 43 patients enrolled, and 37 were evaluable.
- Combination with HF-10 does not appear to exacerbate Ipilimumab toxicity.
- The combination treatment with Ipilimumab and oncolytic virus, HF-10 improved the response rate of Ipilimumab alone. It suggests that it is a potential novel therapeutic approach for metastatic melanoma.
The results will be also presented in the 2016 the Japanese Society of Medical Oncology Annual Meeting scheduled from July 28 at Kobe International Conference Center (Kobe) and in Japan Society of Gene and Cell Therapy scheduled from 28 July at Venue Toranomon Hills Forum (Tokyo).